<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674970</url>
  </required_header>
  <id_info>
    <org_study_id>9977</org_study_id>
    <secondary_id>R21DA038775</secondary_id>
    <nct_id>NCT03674970</nct_id>
  </id_info>
  <brief_title>Effects of Random Nicotine Delivery on Smoking Cessation</brief_title>
  <official_title>Effects of Random Nicotine Delivery on Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether treatment with random nicotine delivery&#xD;
      via a nicotine film both before and after the target quit date will facilitate smoking&#xD;
      cessation relative to treatment with steady state delivery or placebo.&#xD;
&#xD;
      The investigators hypothesize that smoking cessation will be greater in subjects assigned to&#xD;
      a random nicotine delivery regimen (as compared to those assigned to a steady state or&#xD;
      placebo regimen). The nicotine film product is not part of the standard of care and is not&#xD;
      available in non-investigational settings in the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a prospective parallel-group, randomized, double-blind, placebo-controlled&#xD;
      study in which 45 current cigarette smokers who are interested in quitting will be randomly&#xD;
      allocated to one of three possible nicotine film treatment regimens:&#xD;
&#xD;
        1. Random nicotine delivery (a combination of four 0 mg and 4 mg films daily not to exceed&#xD;
           three non-consecutive 4 mg films in one day and to maintain an average of 8 mg of&#xD;
           nicotine per day through 7 days for 6 weeks total).&#xD;
&#xD;
        2. Steady state nicotine delivery (2, 2, 2, 2 mg films daily for 6 weeks total)&#xD;
&#xD;
        3. Placebo delivery (0, 0, 0, 0 mg films daily for 6 weeks total)&#xD;
&#xD;
      Prior to assignment in one of the above treatment groups, all participants will take part in&#xD;
      a 1-week baseline period to assess normal smoking behavior and nicotine dependence. Following&#xD;
      randomization to their assigned treatment group at Visit 2, participants will be instructed&#xD;
      to smoke cigarettes as they feel necessary over the next two weeks while using the nicotine&#xD;
      films as directed (i.e., one film every 3-4 hours for a total of four films per day). After&#xD;
      two weeks of pre-cessation treatment, participants will be asked completely cease cigarette&#xD;
      smoking and to only use their assigned nicotine films as directed. Participants will be&#xD;
      supported in their quitting efforts with regular contacts both in person at the Penn State&#xD;
      Milton S. Hershey Medical Center and over the phone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">November 25, 2019</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Cigarettes Smoked Per Day (CPD)</measure>
    <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
    <description>CPD is measured with the use of daily cigarette logs which are completed daily by participants and returned to the study center at each visit. The CPD measure will be the average of the past 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Exhaled Carbon Monoxide (CO) Measurement</measure>
    <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
    <description>Mean change in exhaled CO (parts per million [ppm])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Questionnaire of Smoking Urges-Brief (QSU-Brief) Total Score</measure>
    <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
    <description>The QSU-Brief, with a possible total score range of 10 to 70, is an instrument used to measure cigarette craving. A score of 10 on this scale indicates very low cigarette craving, while a score of 70 indicates very high cigarette craving.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fagerstrom Test for Nicotine Dependence (FTND) Total Score</measure>
    <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
    <description>Nicotine dependence will be assessed via the FTND, a measure with total scores ranging from 0 (very low dependence) to 10 (very high dependence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Ratings Scale for Nicotine Film Use</measure>
    <time_frame>4 weeks after Target Quit Date</time_frame>
    <description>The scale is comprised of 21 items. Each item is rated on a scale 1-7, where 1 is equal to not at all and 7 is equal to extremely. The total score is the average score of all 21 items. The total score ranges from 1-7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects From Nicotine Film Use</measure>
    <time_frame>4 weeks after Target Quit Date</time_frame>
    <description>Total score ranges from 0 - 36 with lower scores indicating lesser side effects.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Cigarette Smoking</condition>
  <condition>Smoking (Tobacco) Addiction</condition>
  <arm_group>
    <arm_group_label>Random Nicotine Delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steady State Nicotine Delivery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Film</intervention_name>
    <description>Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_label>Random Nicotine Delivery</arm_group_label>
    <arm_group_label>Steady State Nicotine Delivery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-55&#xD;
&#xD;
          -  Smoke ≥10 cigarettes/day for at least the past 12 months&#xD;
&#xD;
          -  Exhaled CO measurement ≥6 ppm at baseline visit&#xD;
&#xD;
          -  Interested in completely ceasing cigarette consumption and using a nicotine film&#xD;
             product as directed&#xD;
&#xD;
          -  Willing to attend regular visits over a 6-week period (not planning to move, not&#xD;
             planning extended vacation, no planned surgeries)&#xD;
&#xD;
          -  Able to read and write in English&#xD;
&#xD;
          -  Able to understand and consent to study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable or significant medical conditions and conditions such as elevated blood&#xD;
             pressure (systolic &gt;159 mmHg or diastolic &gt;99mmHg at baseline), COPD, and those&#xD;
             conditions that are likely to affect biomarker data such as kidney or liver disease&#xD;
&#xD;
          -  Individuals with sodium-restricted diet, heart disease, recent heart attack, irregular&#xD;
             heartbeat, stomach ulcers, or diabetes as well as those taking prescription&#xD;
             medications for depression or asthma as indicated under &quot;Warnings&quot; section on FDA&#xD;
             approved NRT Drug Facts Label&#xD;
&#xD;
          -  More than weekly use in the past 3 months of illegal drugs or prescription drugs that&#xD;
             are not being used for medically prescribed purposes&#xD;
&#xD;
          -  Use of non-cigarette nicotine delivery product in the prior 7 days (including cigars,&#xD;
             pipes, chew, snus, hookah, electronic cigarette and marijuana mixed with tobacco)&#xD;
&#xD;
          -  Use of an FDA approved cessation medication in the past 7 days (any NRT, Chantix,&#xD;
             Wellbutrin)&#xD;
&#xD;
          -  Women who are pregnant (verified by urine pregnancy test at baseline visit), trying to&#xD;
             become pregnant, or nursing&#xD;
&#xD;
          -  Uncontrolled mental illness or substance abuse or inpatient treatment for these&#xD;
             conditions in the past 6 months&#xD;
&#xD;
          -  Any previous adverse reaction to NRT&#xD;
&#xD;
          -  Any other condition, serious illness, or situation that would, in the investigator's&#xD;
             opinion, make it unlikely that the participant could comply with the study protocol&#xD;
&#xD;
          -  Other member of household currently participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia S Grigson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Foulds, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Sciamanna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <results_first_submitted>November 24, 2020</results_first_submitted>
  <results_first_submitted_qc>January 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>January 3, 2021</last_update_submitted>
  <last_update_submitted_qc>January 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Patricia Sue Grigson</investigator_full_name>
    <investigator_title>Director, Penn State Addiction Center for Translation and Professor of Neural and Behavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>nicotine film</keyword>
  <keyword>nicotine delivery</keyword>
  <keyword>random nicotine delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03674970/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Random Nicotine Delivery</title>
          <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
        <group group_id="P2">
          <title>Steady State Nicotine Delivery</title>
          <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Control</title>
          <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Random Nicotine Delivery</title>
          <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
        <group group_id="B2">
          <title>Steady State Nicotine Delivery</title>
          <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
        <group group_id="B3">
          <title>Placebo Control</title>
          <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="9.2"/>
                    <measurement group_id="B2" value="44.0" spread="8.1"/>
                    <measurement group_id="B3" value="43.2" spread="5.8"/>
                    <measurement group_id="B4" value="43.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes Per Day</title>
          <units>Cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.6" spread="7.7"/>
                    <measurement group_id="B2" value="18.8" spread="6.6"/>
                    <measurement group_id="B3" value="16.8" spread="4.5"/>
                    <measurement group_id="B4" value="18.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerstrom Test for Nicotine Dependence Total Score</title>
          <description>The Fagerstrom Test for Nicotine Dependence is a 6 item questionnaire to assess dependence on cigarettes. The total score is a sum of each item's score. The range of the total score is 1-10. Scores indicate the following: 1-2 = very low dependence; 3-4 = low dependence; 5 = moderate dependence; 6-7 = high dependence; 8+ = very high dependence.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="1.4"/>
                    <measurement group_id="B2" value="4.9" spread="1.1"/>
                    <measurement group_id="B3" value="4.3" spread="1.8"/>
                    <measurement group_id="B4" value="4.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Cigarettes Smoked Per Day (CPD)</title>
        <description>CPD is measured with the use of daily cigarette logs which are completed daily by participants and returned to the study center at each visit. The CPD measure will be the average of the past 7 days.</description>
        <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Nicotine Delivery</title>
            <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O2">
            <title>Steady State Nicotine Delivery</title>
            <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Cigarettes Smoked Per Day (CPD)</title>
          <description>CPD is measured with the use of daily cigarette logs which are completed daily by participants and returned to the study center at each visit. The CPD measure will be the average of the past 7 days.</description>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="6.1"/>
                    <measurement group_id="O2" value="-9.0" spread="8.0"/>
                    <measurement group_id="O3" value="-7.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.55</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Exhaled Carbon Monoxide (CO) Measurement</title>
        <description>Mean change in exhaled CO (parts per million [ppm])</description>
        <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Nicotine Delivery</title>
            <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O2">
            <title>Steady State Nicotine Delivery</title>
            <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Exhaled Carbon Monoxide (CO) Measurement</title>
          <description>Mean change in exhaled CO (parts per million [ppm])</description>
          <units>parts per million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" spread="18.6"/>
                    <measurement group_id="O2" value="-5.9" spread="13.4"/>
                    <measurement group_id="O3" value="-10.5" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.2146</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Questionnaire of Smoking Urges-Brief (QSU-Brief) Total Score</title>
        <description>The QSU-Brief, with a possible total score range of 10 to 70, is an instrument used to measure cigarette craving. A score of 10 on this scale indicates very low cigarette craving, while a score of 70 indicates very high cigarette craving.</description>
        <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Nicotine Delivery</title>
            <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O2">
            <title>Steady State Nicotine Delivery</title>
            <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Questionnaire of Smoking Urges-Brief (QSU-Brief) Total Score</title>
          <description>The QSU-Brief, with a possible total score range of 10 to 70, is an instrument used to measure cigarette craving. A score of 10 on this scale indicates very low cigarette craving, while a score of 70 indicates very high cigarette craving.</description>
          <units>QSU Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.55" spread="1.46"/>
                    <measurement group_id="O2" value="-.55" spread="1.36"/>
                    <measurement group_id="O3" value="-.11" spread=".97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.5642</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fagerstrom Test for Nicotine Dependence (FTND) Total Score</title>
        <description>Nicotine dependence will be assessed via the FTND, a measure with total scores ranging from 0 (very low dependence) to 10 (very high dependence).</description>
        <time_frame>Baseline and 4 weeks after Target Quit Date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Nicotine Delivery</title>
            <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O2">
            <title>Steady State Nicotine Delivery</title>
            <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fagerstrom Test for Nicotine Dependence (FTND) Total Score</title>
          <description>Nicotine dependence will be assessed via the FTND, a measure with total scores ranging from 0 (very low dependence) to 10 (very high dependence).</description>
          <units>FTND Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.44"/>
                    <measurement group_id="O2" value="-.53" spread=".92"/>
                    <measurement group_id="O3" value="-.53" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.4353</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Ratings Scale for Nicotine Film Use</title>
        <description>The scale is comprised of 21 items. Each item is rated on a scale 1-7, where 1 is equal to not at all and 7 is equal to extremely. The total score is the average score of all 21 items. The total score ranges from 1-7.</description>
        <time_frame>4 weeks after Target Quit Date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Nicotine Delivery</title>
            <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O2">
            <title>Steady State Nicotine Delivery</title>
            <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ratings Scale for Nicotine Film Use</title>
          <description>The scale is comprised of 21 items. Each item is rated on a scale 1-7, where 1 is equal to not at all and 7 is equal to extremely. The total score is the average score of all 21 items. The total score ranges from 1-7.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread=".71"/>
                    <measurement group_id="O2" value="2.82" spread=".46"/>
                    <measurement group_id="O3" value="2.74" spread=".57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.0348</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects From Nicotine Film Use</title>
        <description>Total score ranges from 0 - 36 with lower scores indicating lesser side effects.</description>
        <time_frame>4 weeks after Target Quit Date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Nicotine Delivery</title>
            <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O2">
            <title>Steady State Nicotine Delivery</title>
            <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects From Nicotine Film Use</title>
          <description>Total score ranges from 0 - 36 with lower scores indicating lesser side effects.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.77" spread="4.32"/>
                    <measurement group_id="O2" value="15.36" spread="3.32"/>
                    <measurement group_id="O3" value="17.13" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.4040</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at each follow-up visit over a period of 7 weeks total.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Random Nicotine Delivery</title>
          <description>One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
        <group group_id="E2">
          <title>Steady State Nicotine Delivery</title>
          <description>One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Control</title>
          <description>One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.&#xD;
Nicotine Film: Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.&#xD;
The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Patricia Sue Grigson</name_or_title>
      <organization>Penn State College of Medicine</organization>
      <phone>717-531-5772</phone>
      <email>pgrigsonkennedy@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

